GENE ONLINE|News &
Opinion
Blog

2022-05-18| Funding

Kriya Bags $270 Million Series C to Support Integrated Gene Therapies

by Joy Lin
Share To

Gene therapy company Kriya Therapeutics enjoyed a $270 million Series C funding round that will aid the advancement of its pipeline and the scaling-up of its engineering, production and computational platforms. 

The financing was led by Patient Square Capital, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF T1D Fund, Lightswitch Capital, Narya Capital, QVT. Transhuman Capital, and other undisclosed investors. 

 

Expanding Gene Therapy Pipeline and Production

 

Earlier this year, Redwood City, California-based Kriya acquired Warden Bio, a Duke University spinout developing gene therapies for glycogen storage disorders. The buyout came with five preclinical gene therapies, allowing Kriya to set up a rare disease division. 

In recent months, the company began operations in its GMP manufacturing plant in Research Triangle Park, North Carolina to support in-house production from early to late stage development. 

Kriya aso scaled SIRVE, its machine-learning-enabled technology and cloud computing architecture to help integrate the large datasets generated by the company’s high throughput screening, next generation sequencing and algorithmic data mining platforms.

The company has also been busy with collaborations. Soon after buying Warden Bio, Kriya entered an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license gene therapies for atrophic age-related macular degeneration, a common progressive retinal disease, and other ocular diseases. 

In March, the company teamed up with Twist Bioscience to discover antibodies that can be delivered by adeno-associated viral (AAV) gene therapy for indications in oncology. 

The amount raised by Kriya in its Series C round was more than double that of its $100 million Series B last July. This builds on the $80.5 million raised by the company in a Series A in May 2020.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
These Pharma Companies Are Laying Off Employees Due to Restructuring
2022-06-30
US Bio-Entrepreneur Program Launches in the UK
2022-06-30
R&D
Saudi Arabia to Invest $3.4 Billion in Latest Push to Develop Biotechnology Presence
2022-06-29
LATEST
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
2022-07-05
Breakthrough Zebrafish Genome Database Now Available
2022-07-05
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Sanofi Launches Nonprofit Brand To Distribute Medicines to Low-Income Countries
2022-07-05
As Private Equity Sale Becomes Less Likely, Novartis May Gravitate Towards Sandoz Spinoff
2022-07-04
Ascletis Begins Study of PD-L1 Antibody Candidate Against HIV
2022-07-04
Akebia Therapeutics Gains $55M Following Deal Termination by Otsuka Pharmaceutical
2022-07-04
EVENT
2022-07-27
BIO Asia–Taiwan 2022
Online and on-side
2022-08-03
BIOPLUS-INTERPHEX KOREA
Seoul
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top